Organon (OGN) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $1.61 billion, flat year-over-year as reported, up 2% at constant currency, with strong growth in Women's Health and Biosimilars, and a slight decline in Established Brands.

• Adjusted EBITDA was $513 million (31.9% margin), and adjusted diluted EPS was $1.12; net income was $195 million, with non-GAAP adjustments including $15 million in IPR&D and milestones.

• Key growth drivers included Nexplanon (up 13% ex-FX), Diprospan (recovery from prior issues), and Hadlima (biosimilar US launch), while NuvaRing and Zetia/Vytorin declined due to competition and VBP.

• 75% of year-to-date sales were generated outside the US, with notable growth in the US and Latin America, Middle East, Russia, and Africa.

• Management affirmed full-year 2024 revenue and Adjusted EBITDA margin guidance.

Financial highlights

• Adjusted gross margin for Q2 was 62.0%, down from 62.9% in Q2 2023, mainly due to product mix, FX, and inflation.

• Adjusted EBITDA margin was 31.9%, down from 33.0% in Q2 2023.

• Non-GAAP adjusted net income for Q2 was $289 million ($1.12 per diluted share), down from $336 million ($1.31) in Q2 2023.

• Free cash flow before one-time spin-related costs was $455 million for 1H 2024; full-year target is ~$1 billion.

• Cash and cash equivalents were $704 million; total debt at $8.7 billion as of June 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance narrowed to $6.25–$6.45 billion, representing 2%–4.7% constant currency growth.

• Adjusted EBITDA margin guidance remains at 31%–33% for the full year.

• R&D expense guidance updated to $430M–$530M, including $30M of IPR&D and milestone expense year-to-date.

• Volume growth expected to accelerate in the second half, offsetting increased LOE, VBP, and price headwinds.

• Non-GAAP effective tax rate for 2024 expected in the 18.5%–20.5% range.